Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 152-162

  Rook, Graham A W ^a   Dheda, Keertan ^a   Zumla, Alimuddin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allergies; Autoimmunity; Environmental saprophytes; Helminths; IFN ; IL 4; IL 4 2; Inflammatory bowel disease; Regulatory T cells

Indexed keywords

AG85B ESAT 6 FUSION PROTEIN; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GENE PRODUCT; HYBRID PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; LIVE VACCINE; PROTEIN AG85A; TRANSCRIPTION FACTOR FOXP3; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

AEROSOL; APOPTOSIS; ARTICLE; BACTERIAL TRANSMISSION; BCG VACCINATION; CELL FUNCTION; CHLORINATION; DELAYED HYPERSENSITIVITY; DEVELOPING COUNTRY; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; ENVIRONMENTAL EXPOSURE; EPIDEMIC; EUROPE; EXPRESSION VECTOR; FATALITY; GEOGRAPHIC DISTRIBUTION; HELMINTHIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION PREVENTION; INFECTION SENSITIVITY; INHIBITION KINETICS; INNATE IMMUNITY; LABORATORY; LATENT PERIOD; LIFESTYLE; LUNG FIBROSIS; MACROPHAGE; MICROBIAL ATTENUATION; MICROBIOLOGY; MOLECULAR EVOLUTION; MOLECULAR MIMICRY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEEDLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT MUCOSA; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TH3 CELL; TUBERCULOSIS; UNITED STATES; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; WALDEYER RING; WATER TREATMENT;

EID: 33646173044     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.018     Document Type: Note

References (118)

1. Wilson M.E., Fineberg H.V., and Colditz G.A. Geographic latitude and the efficacy of Bacillus Calmette-Guerin vaccine. Clin Infect Dis 20 (1995) 982-991
2. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994) 698-702
3. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
4. Strachan D., Sibbald B., Weiland S., Ait-Khaled N., et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 8 (1997) 161-176
5. Gale E.A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 51 (2002) 3353-3361
6. Poser S., Stickel B., Krtsch U., Burckhardt D., et al. Increasing incidence of multiple sclerosis in South Lower Saxony, Germany. Neuroepidemiology 8 (1989) 207-213
7. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002) 911-920
8. Sawczenko A., Sandhu B.K., Logan R.F., Jenkins H., et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 357 (2001) 1093-1094
9. Lindberg E., Lindquist B., Holmquist L., and Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995. J Pediatr Gastroenterol Nutr 30 (2000) 259-264
10. Stene L.C., and Nafstad P. Relation between occurrence of type 1 diabetes and asthma. Lancet 357 (2001) 607
11. Akdis M., Verhagen J., Taylor A., Karamloo F., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 (2004) 1567-1575
12. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
13. Kriegel M.A., Lohmann T., Gabler C., Blank N., et al. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 199 (2004) 1285-1291
14. Karlsson M.R., Rugtveit J., and Brandtzaeg P. Allergen-responsive CD4+ CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 199 (2004) 1679-1688
15. Perez-Machado M.A., Ashwood P., Thomson M.A., Latcham F., et al. Reduced transforming growth factor-beta1-producing T cells in the duodenal mucosa of children with food allergy. Eur J Immunol 33 (2003) 2307-2315
16. Makita S., Kanai T., Oshima S., Uraushihara K., et al. CD4+ CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 173 (2004) 3119-3130
17. Powrie F., Read S., Mottet C., Uhlig H., et al. Control of immune pathology by regulatory T cells. Novartis Found Symp 252 (2003) 92-98
18. Kraus T.A., Toy L., Chan L., Childs J., et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126 (2004) 1771-1778
19. Duchmann R., Kaiser I., Hermann E., Mayet W., et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102 (1995) 448-455
20. Wildin R.S., Smyk-Pearson S., and Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39 (2002) 537-545
21. Rook G.A., Adams V., Hunt J., Palmer R., et al. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol 25 (2004) 237-255
22. Smits H.H., Engering A., van der Kleij D., de Jong E.C., et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115 (2005) 1260-1267
23. Ciprandi G., Vizzaccaro A., Cirillo I., and Tosca M.A. Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study. Allergy Immunol (Paris) 37 (2005) 129-134
24. Yazdanbakhsh M., Kremsner P.G., and van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 296 (2002) 490-494
25. Zuany-Amorim C., Sawicka E., Manlius C., Le Moine A., et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 8 (2002) 625-629
26. Adams V.C., Hunt J., Martinelli R., Palmer R., et al. Mycobacterium vaccae induces a population of pulmonary antigen presenting cells that have regulatory potential in allergic mice. Eur J Immunol 34 (2004) 631-638
27. van der Kleij D., Latz E., Brouwers J.F., Kruize Y.C., et al. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization. J Biol Chem 277 (2002) 48122-48129
28. Rook G.A., and Brunet L.R. Microbes, immunoregulation, and the gut. Gut 54 (2005) 317-320
29. Arkwright P.D., and David T.J. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol 149 (2003) 1029-1034
30. Summers R.W., Elliott D.E., Urban Jr. J.F., Thompson R.A., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005) 825-832
31. Summers R.W., Elliott D.E., Urban Jr. J.F., Thompson R., et al. Trichuris suis therapy in Crohn's disease. Gut 54 (2005) 87-90
32. Kalliomaki M., Salminen S., Arvilommi H., Kero P., et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357 (2001) 1076-1079
33. Arriaga A.K., Orozco E.H., Aguilar L.D., Rook G.A.W., et al. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 128 (2002) 229-237
34. Silva C.L., Bonato V.L., Coelho-Castelo A.A., De Souza A.O., et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 12 (2005) 281-287
35. Hernandez-Pando R., Jeyanathan M., Mengistu G., Aguilar D., et al. Persistence of DNA from M. tuberculosis in superficially normal lung tissue during latent infection. Lancet 356 (2000) 2133-2138
36. Dheda K., Booth H., Huggett J.F., Johnson M.A., et al. Lung remodeling in pulmonary tuberculosis. J Infect Dis 192 (2005) 1201-1209
37. Tramontana J.M., Utaipat U., Molloy A., Akarasewi P., et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1 (1995) 384-397
38. Lee C.G., Homer R.J., Zhu Z., Lanone S., et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194 (2001) 809-821
39. Seah G.T., Scott G.M., and Rook G.A. Type 2 Cytokine Gene Activation and its Relationship to Extent of Disease in Patients with Tuberculosis. J Infect Dis 181 (2000) 385-389
40. Hernandez-Pando R., Aguilar D., Garcia Hernandez M.L., Orozco H., et al. Pulmonary tuberculosis in Balb/c mice with non-functional IL-4 genes; changes in the inflammatory effects of TNF-a and in the regulation of fibrosis. Eur J Immunol 34 (2004) 174-183
41. Wangoo A., Sparer T., Brown I.N., Snewin V.A., et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166 (2001) 3432-3439
42. Lawrence C.E., Paterson J.C., Higgins L.M., MacDonald T.T., et al. IL-4-regulated enteropathy in an intestinal nematode infection. Eur J Immunol 28 (1998) 2672-2684
43. Wynn T.A., Cheever A.W., Jankovic D., Poindexter R.W., et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376 (1995) 594-596
44. Pina A., Valente-Ferreira R.C., Molinari-Madlum E.E., Vaz C.A., et al. Absence of interleukin-4 determines less severe pulmonary paracoccidioidomycosis associated with impaired Th2 response. Infect Immun 72 (2004) 2369-2378
45. North R.J. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 113 (1998) 55-58
46. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., et al. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65 (1997) 623-629
47. Hernandez-Pando R., Pavon L., Arriaga K., Orozco H., et al. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect Immun 65 (1997) 3317-3327
48. Rook G.A., Hernandez-Pando R., Dheda K., and Seah G.T. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 (2004) 483-488
49. Fine P.E., Floyd S., Stanford J.L., Nkhosa P., et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 126 (2001) 379-387
50. Malhotra I., Mungai P., Wamachi A., Kioko J., et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 162 (1999) 6843-6848
51. Bretscher P.A. Prospects for low dose BCG vaccination against tuberculosis. Immunobiology 191 (1994) 548-554
52. Rook G., Dheda K., and Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 23 (2005) 2115-2120
53. Lin Y., Zhang M., Hofman F.M., Gong J., et al. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 64 (1996) 1351-1356
54. Dheda K., Huggett J.F., Bustin S.A., Johnson M.A., et al. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37 (2004) 112-114 6, 8-9
55. Dheda K., Chang J.-.S., Breen R.A., Kim L.U., et al. In vivo and in vitro studies of a novel cytokine, Interleukin-4delta2, in pulmonary tuberculosis. Am J Resp Crit Care Med 172 (2005) 501-508
56. Atamas S.P., Choi J., Yurovsky V.V., and White B. An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation. J Immunol 156 (1996) 435-441
57. Vasiliev A.M., Vasilenko R.N., Kulikova N.L., Andreev S.M., et al. Structural and functional properties of IL-4delta2, an alternative splice variant of human IL-4. J Proteome Res 2 (2003) 273-281
58. Gautherot I., Burdin N., Seguin D., Aujame L., et al. Cloning of interleukin-4 delta2 splice variant (IL-4delta2) in chimpanzee and cynomolgus macaque: phylogenetic analysis of delta2 splice variant appearance, and implications for the study of IL-4-driven immune processes. Immunogenetics 54 (2002) 635-644
59. Yatsenko O.P., Filipenko M.L., Voronina E.N., Khrapov E.A., et al. Alternative splicing of murine interleukin-4 mRNA. Bull Exp Biol Med 137 (2004) 179-181
60. Seah G.T., Gao P.S., Hopkin J., and Rook G.A.W. Interleukin-4 and its alternatively spliced variant (IL-4d2) in atopic asthmatics. Am J Resp Crit Care Med 164 (2001) 1016-1018
61. Fletcher H.A., Owiafe P., Jeffries D., Hill P., et al. Increased expression of mRNA encoding IL-4 and its splice variant IL-4d2 in cells from contacts of Mycobacterium tuberculosis in the absence of in vitro stimulation. Immunology 112 (2004) 669-673
62. Demissie A., Abebe M., Aseffa A., Rook G.A.W., et al. Healthy individuals that control latent infection with M. tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172 (2004) 6938-6943
63. Manca C., Reed M.B., Freeman S., Mathema B., et al. Differential Monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun 72 (2004) 5511-5514
64. Barker R.D., and Millard F.J. High death rates for tuberculosis patients in rural South Africa. Int J Tuberc Lung Dis 2 (1998) 1049-1050
65. Wilkinson D., and Moore D.A. HIV-related tuberculosis in South Africa-clinical features and outcome. S Afr Med J 86 (1996) 64-67
66. Anderson M.C. On Koch's treatment. Lancet i (1891) 651-652
67. Bogdan C., Vodovotz Y., Paik J., Xie Q.W., et al. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol 55 (1994) 227-233
68. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3 (2003) 23-35
69. Voskuil M.I., Schnappinger D., Visconti K.C., Harrell M.I., et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198 (2003) 705-713
70. Balcewicz-Sablinska M.K., Keane J., Kornfeld H., and Remold H.G. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 161 (1998) 2636-2641
71. Riendeau C.J., and Kornfeld H. THP-1 cell apoptosis in response to Mycobacterial infection. Infect Immun 71 (2003) 254-259
72. Spira A., Carroll J.D., Liu G., Aziz Z., et al. Apoptosis genes in human alveolar macrophages infected with virulent or attenuated Mycobacterium tuberculosis: a pivotal role for tumor necrosis factor. Am J Respir Cell Mol Biol 29 (2003) 545-551
73. Keane J., Shurtleff B., and Kornfeld H. TNF-dependent BALB/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-gamma independent manner. Tuberculosis (Edinb) 82 (2002) 55-61
74. Molloy A.P., Laochumroonvorapong P., and Kaplan G. Apoptosis but not necrosis of infected monocytes is coupled with killing of intracellular Bacille Calmette-Guérin. J Exp Med 180 (1994) 1499
75. Oddo M., Renno T., Attinger A., Bakker T., et al. Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 160 (1998) 5448-5454
76. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
77. Fratazzi C., Arbeit R.D., Carini C., Balcewicz-Sablinska M.K., et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 66 (1999) 763-764
78. Durrbaum-Landmann I., Gercken J., Flad H.D., and Ernst M. Effect of in vitro infection of human monocytes with low numbers of Mycobacterium tuberculosis bacteria on monocyte apoptosis. Infect Immun 64 (1996) 5384-5389
79. Essner R., Rhoades K., McBride W.H., Morton D.L., et al. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 142 (1989) 3857-3861
80. Joyce D.A., and Steer J.H. IL-4, IL-10 and IFN-gamma have distinct, but interacting, effects on differentiation-induced changes in TNF-alpha and TNF receptor release by cultured human monocytes. Cytokine 8 (1996) 49-57
81. Maerten P, Shen C, Bullens DM, Van Assche G, et al. Effects of interleukin 4 on CD25(+) CD4(+) regulatory T cell function. J Autoimmun 2005.
82. Ordway D.J., Costa L., Martins M., Silveira H., et al. Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190 (2004) 756-766
83. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 10 (2004) 801-805
84. Stock P., Akbari O., Berry G., Freeman G.J., et al. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol 5 (2004) 1149-1156
85. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195 (2002) 603-616
86. Bisikirska B, Colgan J, Luban J, Bluestone JA, et al. TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J Clin Invest 2005.
87. Jarvis LB, Matyszak MK, Duggleby RC, Goodall JC, et al. Autoreactive human peripheral blood CD8(+) T cells with a regulatory phenotype and function. Eur J Immunol 2005.
88. Delgado J.C., Tsai E.Y., Thim S., Baena A., et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci USA 99 (2002) 7576-7581
89. Boussiotis V.A., Tsai E.Y., Yunis E.J., Thim S., et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 105 (2000) 1317-1325
90. Guerkov R.E., Targoni O.S., Kreher C.R., Boehm B.O., et al. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J Immunol Methods 279 (2003) 111-121
91. Fiorenza G., Rateni L., Farroni M.A., Bogue C., et al. TNF-alpha, TGF-beta and NO relationship in sera from tuberculosis (TB) patients of different severity. Immunol Lett 98 (2005) 45-48
92. Toossi Z., and Ellner J.J. The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol 87 (1998) 107-114
93. Gerosa F., Nisii C., Righetti S., Micciolo R., et al. CD4(+) T cell clones producing both interferon-gamma and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol 92 (1999) 224-234
94. Schwander S.K., Torres M., Sada E., Carranza C., et al. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. J Infect Dis 178 (1998) 1434-1445
95. Somoskovi A., Zissel G., Zipfel P.F., Ziegenhagen M.W., et al. Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis. Eur Cytokine Network 10 (1999) 135-142
96. Mazzarella G., Bianco A., Perna F., D'Auria D., et al. T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin Exp Immunol 132 (2003) 283-288
97. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
98. Kaufmann S.H., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11 (2005) S33-S44
99. Vekemans J., Ota M.O., Sillah J., Fielding K., et al. Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun 72 (2004) 381-388
100. Black G.F., Weir R.E., Chaguluka S.D., Warndorff D., et al. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults. Clin Diagn Lab Immunol 10 (2003) 602-611
101. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171 (2003) 1602-1609
102. Tanghe A., D'Souza S., Rosseels V., Denis O., et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 69 (2001) 3041-3047
103. Leal I.S., Smedegard B., Andersen P., and Appelberg R. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation. Immunology 104 (2001) 157-161
104. Skinner M.A., Ramsay A.J., Buchan G.S., Keen D.L., et al. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108 (2003) 548-555
105. Biet F., Kremer L., Wolowczuk I., Delacre M., et al. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 70 (2002) 6549-6557
106. Rook G.A.W., Dheda K., and Zumla A. Immune responses to TB in developing countries: implications for new vaccines. Nat Rev Immmunol 5 (2005) 661-667
107. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
108. Amato Neto V., de Oliveira e Silva Y.K., Finger H., Bianchi A., et al. Analysis of the adverse effects occuring after the administration of BCG by oral route in 5,579 healthy children. Rev Paul Med 82 (1973) 135-138
109. Kahn H., Meyerheim R., Azulay R.D., and Scorzelli A. BCG vaccination: a comparison of post-vaccination tuberculin sensitivity after oral and intradermal vaccination of newborn infants. Tubercle 51 (1970) 423-429
110. Hoft D.F., Brown R.M., and Belshe R.B. Mucosal Bacille Calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis 30 Suppl 3 (2000) S217-S222
111. Doherty T.M., Olsen A.W., van Pinxteren L., and Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 70 (2002) 3111-3121
112. Lagranderie M., Ravisse P., Marchal G., Gheorghiu M., et al. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuberc Lung Dis 74 (1993) 38-46
113. Falero-Diaz G., Challacombe S., Banerjee D., Douce G., et al. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18 (2000) 3223-3229
114. Chen L., Wang J., Zganiacz A., and Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 72 (2004) 238-246
115. Santosuosso M., Zhang X., McCormick S., Wang J., et al. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 174 (2005) 7986-7994
116. Haile M., Hamasur B., Jaxmar T., Gavier-Widen D., et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb) 85 (2005) 107-114
117. Tree J.A., Williams A., Clark S., Hall G., et al. Intranasal Bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol 138 (2004) 405-409
118. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 (2001) 21-42